These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. Muramoto O; Sugishita M; Ando K J Neurol Neurosurg Psychiatry; 1984 May; 47(5):485-91. PubMed ID: 6736979 [TBL] [Abstract][Full Text] [Related]
8. Long-term administration of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Davis KL; Mohs RC Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611 [TBL] [Abstract][Full Text] [Related]
12. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease. Jotkowitz S Ann Neurol; 1983 Dec; 14(6):690-1. PubMed ID: 6360031 [TBL] [Abstract][Full Text] [Related]
13. Physostigmine effects in Alzheimer's disease: relationship to dementia severity. Schwartz AS; Kohlstaedt EV Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944 [TBL] [Abstract][Full Text] [Related]
14. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush S; Guterman A; Villalon AV J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560 [TBL] [Abstract][Full Text] [Related]
15. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Schneider LS; Olin JT; Pawluczyk S Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085 [TBL] [Abstract][Full Text] [Related]
16. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Bierer LM; Aisen PS; Davidson M; Ryan TM; Stern RG; Schmeidler J; Davis KL Alzheimer Dis Assoc Disord; 1993; 7(2):98-104. PubMed ID: 8347333 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262 [TBL] [Abstract][Full Text] [Related]
19. Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer's disease. Molchan SE; Vitiello B; Minichiello M; Sunderland T Arch Gen Psychiatry; 1991 Dec; 48(12):1113-4. PubMed ID: 1845230 [No Abstract] [Full Text] [Related]
20. Memory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388 [No Abstract] [Full Text] [Related] [Next] [New Search]